

ASX ANNOUNCEMENT

Middle East Distribution Agreement – Supplementary Disclosure

13 December 2019. Analytica Ltd (ASX:ALT) Analytica Ltd (ASX: ALT) refers to its announcement on 28 November 2019 and advises that the distributor is Motion for General Supplying's LLC of New Maadi, an entity based in Cairo Egypt. The agreement is current and in effect and contains provisions customarily found in product distribution agreements including in relation to exclusivity, promotion and marketing, reporting, intellectual property, pricing and delivery, target volumes and termination.

Although, at this stage, there is no material financial impact of the Distribution Agreement on Analytica, the Company considers that it represents a new strategic direction being undertaken by the Company.

Authorised for release by the Board.

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance for urinary incontinence in Australia and has CE mark and USFDA 510(k) clearance.

PeriCoach also has clearance in Australia, and CE Marking in Europe for the treatment of pelvic organ prolapse, a condition that affects up to 1 in 5 women during their lifetime.

